AI assistant
Outset Medical, Inc. — Director's Dealing 2021
Apr 5, 2021
33476_dirs_2021-04-05_39b56717-f0ac-403d-a956-b25e2fdaf591.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Outset Medical, Inc. (OM)
CIK: 0001484612
Period of Report: 2021-04-01
Reporting Person: Vazquez Martin (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-04-01 | Common Stock | M | 12716 | $3.88 | Acquired | 21971 | Direct |
| 2021-04-01 | Common Stock | M | 9784 | $3.88 | Acquired | 31755 | Direct |
| 2021-04-01 | Common Stock | S | 19997 | $55.013 | Disposed | 11758 | Direct |
| 2021-04-01 | Common Stock | S | 2503 | $55.3625 | Disposed | 9255 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-04-01 | Performance Stock Option (Right to Buy) | $3.88 | M | 12716 | Disposed | 2027-12-19 | Common Stock (12716) | Direct |
| 2021-04-01 | Performance Stock Option (Right to Buy) | $3.88 | M | 9784 | Disposed | 2027-12-19 | Common Stock (9784) | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $54.23 to $55.222, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1).
F2: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $55.23 to $55.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2).
F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020.
F4: This Form 4 corrects the exercise price previously reported as $3.87 on the Form 3 filed on September 14, 2020.